Pitcairn’s TG Therapeutics TGTX Stock Holding History

Pitcairn’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,493	Closed	-$307K	–	521
2025 Q3	$307K	Sell	8,493 -1,392	-14%	-$45.9K	0.02%	499
2025 Q2	$356K	Sell	9,885 -2,027	-17%	-$75.5K	0.02%	511
2025 Q1	$470K	Buy	11,912 +167	+1%	+$5.62K	0.03%	443
2024 Q4	$354K	Buy	+11,745	New	+$337K	0.02%	533
2024 Q1	–	Sell	-13,623	Closed	-$233K	–	731
2023 Q4	$233K	Buy	13,623 +111	+0.8%	+$1.29K	0.02%	610
2023 Q3	$113K	Buy	13,512 +3,595	+36%	+$50.1K	0.01%	623
2023 Q2	$246K	Buy	+9,917	New	+$256K	0.02%	573

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Pitcairn's TGTX Position: Q4 2025 in Review

Pitcairn sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 8,493 shares — an estimated $307K sold.

Pitcairn first reported a position in TGTX in Q2 2023 and held it in 7 quarters. The position peaked at $470K in Q1 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

Pitcairn reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
Pitcairn sold 8,493 TG Therapeutics shares in Q4 2025, an estimated $307K.
Pitcairn first reported a position in TG Therapeutics in Q2 2023 and held it in 7 quarters.
Pitcairn's TG Therapeutics position peaked at $470K in Q1 2025.
351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.